Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep573 | Endocrine-Related Cancer | ECE2022

Postoperative prediction of tumor recurrence in patients with nonfunctional pancreatic neuroendocrine tumors

Olearska Helena , Sowa-Staszczak Anna , Opalinska Marta , Kurzyńska Anna , Hubalewska-Dydejczyk Alicja

Introduction: Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group with various treatment options depending on grading, staging, and presence of symptoms related to hormonal secretion. Their incidence significantly increased over the past decade and nowadays constitutes 30% of all NETs of the gastrointestinal tract. Despite the evidence of a different malignancy potential of PNETs G2, postoperative management is the same in all patients. Ai...

ea0090ep15 | Adrenal and Cardiovascular Endocrinology | ECE2023

A single center experience of extraadrenal paragangliomas–clinical and molecular analysis

Kurzyńska Anna , Opalinska Marta , Skalniak Anna , Rzepka Ewelina , Gilis-Januszewska Aleksandra , Przybylik-Mazurek Elwira , Hubalewska-Dydejczyk Alicja

Paragangliomas are rare neuroendocrine neoplasms that arise from chromaffin tissue commonly located in the adrenal medulla, pre-aortic and paravertebral sympathetic plexus or skull base. About 30% of paragangliomas have a genetic basis. They may be associated with autosomal dominant inheritance of variants in the gene encoding succinate dehydrogenase or may coexist in genetically determined endocrine syndromes. The study aim was to analyse clinical and molecular data of patien...

ea0081ep764 | Pituitary and Neuroendocrinology | ECE2022

Clinical characteristics, treatment and outcomes of well-differentiated gastroenteropancreatic G3 NET

Opalinska Marta , Staszczak Anna Sowa , Kurzyńska Anna , Morawiec-Sławek Karolina , Stefańska Agnieszka , Hubalewska-Dydejczyk Alicja

Background: Although gastroenteropancreatic neuroendocrine tumors G3 (GEP-NET G3) and neuroendocrine cancers (GEP-NEC G3) are characterized in histopathological examination by Ki67>20% or >20 mitoses/10HPF their management and prognosis is substantially different. Despite the WHO introduces the novel well-differentiated neuroendocrine tumour of high grade (NET G3) classification in 2017 the clinical management of them is still challenging due to high NET G3 heterogenei...

ea0090p6 | Adrenal and Cardiovascular Endocrinology | ECE2023

Patients with NF1 need routine hormonal screening towards pheochromocytoma

Rzepka Ewelina , Bogusławska Anna , Kurzyńska Anna , Opalinska Marta , Przybylik-Mazurek Elwira , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Up to 40% of pheochromocytoma cases have a genetic background. The prevalence of pheochromocytoma in neurofibromatosis type 1 (NF1) was reported to be from 0.1 to 5.7%. However, the actual incidence of pheochromocytoma in NF1 seems to be underestimated. Current recommendations on NF1 do not include systematic biochemical screening for the presence of pheochromocytoma. Our aim was to analyse clinicopathological characteristics of pheochromocytoma in the course of NF1 syndrome w...

ea0090ep7 | Adrenal and Cardiovascular Endocrinology | ECE2023

Clinical symptoms, imaging and hormonal tests that suggest phaeochromocytoma in a patient with a solitary fibrous tumor incidentally discovered in the adrenal gland

Kurzyńska Anna , Nowak Andrzej , Ulatowska-Białas Magdalena , Sierżęga Marek , Bobrzyński Łukasz , Przybylik-Mazurek Elwira , Hubalewska-Dydejczyk Alicja

The solitary fibrous tumor is a rare spindle cell neoplasm, originally described in the pleural cavity. However, it can occur in other locations. SFTs that originate from the adrenal gland tissue are extremely rare. To date, only single cases have been described in the literature. We present a case of a 61-year-old Caucasian man with a SFT of the left adrenal gland. The patient was hospitalized in the internal medicine department due to paroxysmal hypertension (up to 190/100 m...

ea0073aep509 | Pituitary and Neuroendocrinology | ECE2021

Self-administration of long-acting somatostatin analogues in NET patients forced by the COVID-19 pandemic – does it affect the clinical outcome?

Opalinska Marta , Anna Kurzynska , Staszczak Anna Sowa , Joanna Palen-Tytko , Zwinczewska Helena , Karolina Morawiec-Slawek , Hubalewska-Dydejczyk Alicja

BackgroundSomatostatin analogues (SSA) (octreotide and lanreotide) are recommended as a first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of them are usually used in injection repeated every 4 weeks.The study objectiveWas to compare the way of SSA administration (injection performed by profession...

ea0081p676 | Pituitary and Neuroendocrinology | ECE2022

Pheochromocytoma/paraganglioma metastatic potential prediction

Rzepka Ewelina , Kurzyńska Anna , Grochowska Anna , Ulatowska-Białas Magdalena , Skalniak Anna , Lech Martyna , Opalinska Marta , Bogusławska Anna , Przybylik-Mazurek Elwira , Sowa-Staszczak Anna , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumours, which derive from the chromaffin cells of the adrenal medulla or extra-adrenal sympathetic and parasympathetic ganglia. About 15-20% of those neoplasms could present malignant course. Prediction of PPGL metastatic potential still remains a great clinical challenge, since the sensitivity and specificity of proposed prediction systems are not satisfactory. We performed a retrospective database search for ...